At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Bipolar Androgen Therapy Plus Olaparib in Patient With Castration-Resistant Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Olaparib, and 4 other interventions for Castration-Resistant Prostate Carcinoma and Prostate Adenocarcinoma. Completed, enrolled 36 participants across 1 site.
Detailed Summary
This phase II trial studies how well testosterone (enanthate or cypionate) and olaparib work in treating patients with prostate cancer that has progressed despite hormonal therapy. Hormonal therapy, such as leuprolide, may lessen the amount of male sex hormones made by the body. In patients that have developed progressive cancer in spite of standard hormonal treatment (i.e. castration-resistant prostate cancer), administering testosterone may result in regression of tumors by causing DNA damage in cancer cells that have adapted to low testosterone conditions. Olaparib may stop the growth of tumor cells by blocking some of the enzymes involved in repairing DNA damage. Therefore, giving testosterone and olaparib together may work better in treating castration-resistant prostate cancer by generating DNA damage that the cancer cell is unable to repair.
Study Details
Timeline
Interventions
Correlative studies
Given PO
Ancillary studies
Ancillary studies
Given IM
Given IM